This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
In retirement, choosing between Sp500 and Total Market matters. This guide outlines criteria to select the better fit for your horizon and risk profile.
28,409 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
BonkDAO reports a $20 million loss following a governance attack that exploited a proposal flaw. Upbit has paused BON...
As July earnings season looms, investors are scanning three cloud computing stocks before the reports. AI demand and ...
Mortgage lenders are moving AI from experimentation to enterprise deployment in 2026. Addy AI's Michael Vandi explain...
The Fed's Beige Book indicates broad, uneven regional growth through late May and June, with consumer spending up but...
This in-depth guide breaks down Employers EIG 2025 earnings, focusing on Q4 results, guidance, and what it means for ...
Microsoft sits near a long-running price anchor as investors weigh AI incentives against macro risks. A decisive move...
Two decades after a flopped acting debut, David Ellison’s Skydance is moving from indie financier to potential indust...
Target’s new chief executive Michael Fiddelke unveils a candor-driven plan to revive growth after a sales slump. The ...
UBS lifts H World, Wells Fargo reprises Netflix coverage, and JD.com shares a reduced target as institutional views s...
From dining room to boardroom, shark tank’s daymond john built a $350 million empire by rejecting shortcuts and inves...
A sizable $12 million stake in a floor-and-decor retailer arrives as the stock trades off. This article breaks down t...